Vaccine Partners Turn Rivals With First Shot for Advancing Virus [Financial Post (Toronto, Ontario, Canada)]
Valneva SE - American Depositary Shares (VALN)
Company Research
Source: Financial Post
Author of the article: You can save this article by registering for free here . Or sign-in if you have an account. (Bloomberg) — Two European partners will soon be vying for dominance in a new battleground: vaccines to protect travelers against a painful viral illness transmitted by mosquitoes. Valneva SE became the first company to win clearance late last year to sell a shot for chikungunya, a disease that can cause fever and severe joint pain. Bavarian Nordic A/S is some months behind, awaiting approval in the European Union and starting a submission in the US. Article content Article content The companies have marketed and distributed each other's products since 2020, a collaboration due to wind down next year — just as the two start competing to carve a new market for their rival chikungunya shots. Valneva's lead will undoubtedly translate into “a much more significant market share,” according to Chief Executive Officer Thomas Lingelbach. His counterpart at Bavari
Show less
Read more
Impact Snapshot
Event Time:
VALN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALN alerts
High impacting Valneva SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VALN
News
- Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine [Yahoo! Finance]Yahoo! Finance
- Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya VaccineGlobeNewswire
- Valneva SE (NASDAQ: VALN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.MarketBeat
- Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Valneva Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
VALN
Sec Filings
- 5/13/24 - Form 6-K
- 5/7/24 - Form 6-K
- 3/26/24 - Form 6-K
- VALN's page on the SEC website